A detailed history of Two Sigma Investments, LP transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 258,473 shares of ATHA stock, worth $183,515. This represents 0.0% of its overall portfolio holdings.

Number of Shares
258,473
Previous 302,133 14.45%
Holding current value
$183,515
Previous $800,000 85.5%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.42 - $3.43 $18,337 - $149,753
-43,660 Reduced 14.45%
258,473 $116,000
Q2 2024

Aug 14, 2024

SELL
$1.92 - $2.71 $237,066 - $334,609
-123,472 Reduced 29.01%
302,133 $800,000
Q1 2024

May 15, 2024

BUY
$2.24 - $4.15 $272,236 - $504,366
121,534 Added 39.97%
425,605 $1.17 Million
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.46 $51,464 - $91,081
37,025 Added 13.86%
304,071 $738,000
Q3 2023

Nov 14, 2023

SELL
$1.9 - $3.16 $170,325 - $283,278
-89,645 Reduced 25.13%
267,046 $539,000
Q2 2023

Aug 14, 2023

SELL
$2.36 - $3.59 $152,725 - $232,323
-64,714 Reduced 15.36%
356,691 $1.05 Million
Q1 2023

May 15, 2023

BUY
$2.26 - $4.22 $183,213 - $342,106
81,068 Added 23.82%
421,405 $1.05 Million
Q4 2022

Feb 14, 2023

SELL
$2.76 - $3.71 $56,044 - $75,335
-20,306 Reduced 5.63%
340,337 $1.08 Million
Q3 2022

Nov 14, 2022

BUY
$2.93 - $3.96 $240,875 - $325,551
82,210 Added 29.53%
360,643 $1.07 Million
Q2 2022

Aug 15, 2022

BUY
$2.74 - $13.43 $575,882 - $2.82 Million
210,176 Added 307.92%
278,433 $849,000
Q1 2022

May 16, 2022

SELL
$8.96 - $13.51 $838,862 - $1.26 Million
-93,623 Reduced 57.83%
68,257 $921,000
Q4 2021

Feb 14, 2022

SELL
$9.17 - $16.39 $562,313 - $1.01 Million
-61,321 Reduced 27.47%
161,880 $2.11 Million
Q3 2021

Nov 15, 2021

BUY
$9.15 - $11.09 $1.32 Million - $1.6 Million
144,401 Added 183.25%
223,201 $2.09 Million
Q2 2021

Aug 16, 2021

BUY
$10.24 - $20.87 $806,912 - $1.64 Million
78,800 New
78,800 $807,000

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $26.9M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.